Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Circulating nucleosomes predict response to tyrosine kinase inhibitors in hepatocellular carcinoma

Friday, February 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The paper presented by Salani et al. at the EACR 2022 conference discusses the role of circulating nucleosomes in predicting responses to tyrosine kinase inhibitors in hepatocellular carcinoma (HCC). This research highlights the prognostic value of the Nu.Q® cancer test, which could enhance treatment strategies for HCC patients.
Price reaction · baseline $22.1 (2024-02-16T14:38:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close
-5.9%
day 1
-5%
day 3 · peak
-12.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Circulating nucleosomes can predict treatment response.
  • Research presented at a notable conference.
  • Potential for improved patient outcomes in HCC.

Full Press Release Details

Paper titled: Circulating nucleosomes predict response to tyrosine kinase inhibitors in hepatocellular carcinoma (HCC)
Salani et al
Presented at EACR 2022 conference on Liquid Biopsy

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the presented paper?

The paper focuses on how circulating nucleosomes can predict responses to tyrosine kinase inhibitors in hepatocellular carcinoma.

Where was the research presented?

The research was presented at the EACR 2022 conference on Liquid Biopsy.

What is the significance of the Nu.Q® cancer test?

The Nu.Q® cancer test shows prognostic value in predicting treatment responses in HCC.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare hepatocellular carcinoma tyrosine kinase inhibitors Nu.Q® cancer test EACR 2022
Last updated: Feb 16, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk